Summary: With the increasing need for reliable and comprehensive pharmacokinetic data from diverse non clinical as well as clinical studies, a sensitive and specific bioanalytical technique is essential . Such a tech nique is liquid chromatography-mass spectrometry (LC-MS). This article provides a brief overview of the key developments in LC-MS and focuses on the more recent LC-MS ionisation/interfacing technique , that of atmospheric pressure ionisation (API). The advantages of LC-API-MS/MS for routine bioanalysis , in terms of sensitivity, specificity and reproducibility are discussed. Recent scientific literature is cited that exemplifies the capabilities, applications and usefulness of this powerful analytical technique in pharmacoki netics/toxicokinetics studies.
Introduction
Strategies in the drug discovery and drug develop ment processes are undergoing radical change. For ex ample, the contribution of pharmacokinetics to both processes is increasingl,2) Furthermore, toxicokinetics has now become established as an essential part of toxici ty testing3-7). With this emphasis in the use of phar macokinetics/toxicokinetics and the greater potencies of newer drugs, a sensitive and specific bioanalytical technique is essential. In this decade, liquid chro matography-tandem mass spectrometry (LC-MS/MS) has emerged to fulfil that need. LC-MS/MS can be con sidered to be the major bioanalytical advance of this de cade.
The objective of this article is to overview LC-MS/ MS and to exemplify its applications in pharmacokinet ics/toxicokinetics.
Developments in LC-MS: Historical Perspectives
Liquid chromatography is undoubtedly the most im portant and extensively used separation technique presently available for the analysis of pharmaceuticals. Attempts to couple the liquid chromatograph to the mass spectrometer, an inherently sensitive and specific detector, were made over 25 years ago, with varying degrees of success. Coupling a liquid chromatograph to a mass spectrometer has always been problematic due to the considerable quantity of heat that is necessary in ord er to vaporise the relatively large volumes of mobile phase (liquid) used in liquid chromatography. The large quantities of vapour consequently produced are not com patible with the high vacuum necessary for the opera tion of the mass spectrometer. For example, mobile phase from a liquid chromatograph, such as 1 ml of acetonitrile and water (1 : 1, v : v), expands in the typi cal operating pressure (< 10-5 torr) of a mass spectrom eter to some 6 x 107 litres of gas that have to be removed to allow proper instrument operation.
Several review articles have been published on inter facing the liquid chromatograph to the mass spectrome ter, and on applications thereof~12). Among the various interfaces that have been designed to couple the liquid chromatograph to the mass spectrometer are: direct liq uid introduction, moving belt, thermospray, plas maspray, continuous flow fast atom bombardment, and particle beam. All these designs involve ionisation in the high vacuum region. In general, they are mechanically complicated, poorly reproducible, unstable or sample de pendent. For such reasons, LC-MS involving these inter faces was useful only in specialised applications and is not considered amenable to routine use. Table I sum marises some of the major developments in LC-MS in terfaces.
Applications involving routine use of one of the last of the interface designs shown in Table I 
API Interfaces
The two main types of API interface that are in use are (i) electrospray or ionspray (nebulizer assisted) and (ii) atmospheric pressure chemical ionisation (APCI).
Some general guidance on the choice of API interface and on the mode of ionisation is given in Table II. The use of electrospray ionisation for LC-MS was reported in 1984, simultaneously by Yamashita et a117) and Aleksandrov et a11s, 26) . Electrospray ionisation in volves spraying the LC eluent, while applying a high volt age at the tip of the spray, into dry nitrogen at at mospheric pressure to create a dispersion of charged droplets that rapidly evaporate. As the droplets decrease in size, the increase in surface charge density and the decrease in radius of curvature result in electric fields strong enough to desorb solute ions27>. Ionspray combines the principles of electrospray and ion evapora tion but with the addition of a nebulizing gas21). Elec trospray or ionspray tend to be more suitable for polar compounds or compounds that are readily ionised in solu tion. Most of the original electrospray/ionspray inter faces suffer from low solvent flow capacity (typically 5 20,ul/min) such that eluent splitting is necessary when using standard size columns (e.g. 4.6 mm i.d.) for LC separation. Arguably, this may not be an analytical issue as instruments involving such interfaces are concentra tion detectors. Therefore, theoretically, post-column splitting should not compromise sensitivity. However, the demand for direct coupling of the liquid chromato graph to the mass spectrometer without splitting has resulted in the development of a high flow variant of the electrospray that can cope with LC flow rates of up to 1 ml/min. Another variant of electrospray, known as nanospray or nanoelectrospray, has also recently been developed for use with capillary electrophoresis (CE) to cope with eluent flow rate in the region of a few nano litres per minute. The other type of API, atmospheric pressure chemi cal ionisation (APCI), is produced by a corona dis charge that first ionises the solvent molecules which then proceed to ionise the analyte molecules as in the chemical ionisation process. Unlike thermospray, APCI does not rely on the presence of an ionising buffer (such as ammonium acetate) in the mobile phase to induce ioni sation. This interface is also suitable for less polar com pounds. One slight disadvantage of APCI is that the in terface is normally heated to assist vaporisation of sol vent and, consequently, ion fragmentation from thermal ly labile compounds can occur. With the ability to cope with flow rates of up to 1 ml/min from the liquid chro matograph without splitting, this interface has been par ticularly popular for routine bioanalysis before the de velopment of higher flow electrospray.
Since API-based techniques are applicable to a large variety of compound classes, their use with LC can be considered to be even more universal than that of an ultra-violet (UV) absorption detector. However, due to the huge pressure difference that exists between the ion source (at atmospheric pressure) and the mass analyser (at 10-6 torr), which are normally separated by only a fine capillary or orifice, the use of nonvolatile inorganic buffers for LC that may crystallise from the mobile phase is not advisable. For this reason, volatile organic buffers, such as ammonium acetate, formate, etc. are normally used in LC-MS. Ion-pairing reagents are also unsuitable for LC-MS analysis lack if they volatility and due to conductivity problems.
The Choice between LC-MS or LC-MS/MS for Bioanalysis
Although a mass spectrometer is a sensitive and specific detector, bioanalysis at trace levels will be sub jected to interference from coextracted material that has the same mass as the analyte of interest. Thus chromato graphic separation is needed to ensure specificity and this often results in a relatively long chromatographic analysis time. With the advent of appropriate instrumen tation, tandem mass spectrometry is now commonplace. The additional MS stage can enhance specificity and, as a result, reduces the requirement for extensive chro matographic separation or sample clean-up. in nega tive ion mode). In order to produce structurally charac teristic fragments from these quasi-molecular ions (referred to as parent or precursor ions), they are sub jected to collisions with inert gaseous molecules, such as argon or nitrogen; this process occurs in the collision cell of the mass spectrometer and is energetic enough to cause ion dissociation, a process known as collision in duced dissociation (CID). The fragment ions so formed (referred to as daughter or product ions) can then be monitored using the second mass analyser. Fig. 1 shows a schematic diagram of a triple quadrupole LC-MS/MS system. The process of monitoring the transition of the precursor ion to a product ion is known as selected or multiple reaction monitoring (MRM). As an illustra tion, the ion transitions monitored for the bioanalysis of the dihydropyridine, barnidipine are shown in Fig. 2 . These ion transitions are often so specific that when the technique is used as a LC detector in bioanalysis, the chromatograms so produced often contain only a single peak even at picogram per millilitre concentrations. Fig. 3 compares the chromatograms for the bioanalysis of a drug in monkey plasma obtained using either a UV or a MS/MS detector. Triple quadrupole mass spectrometers are the most popular type of tandem mass spectrometer used in bioanalysis. Table III summarises the merits of various types of LC-MS/MS system for bioanalysis. Although the price of a tandem mass spectrometer is typically 50% more than that of the equivalent single mass spec trometer, the improvement in specificity and the reduc tion in the chromatographic analysis time easily justifies the higher capital outlay.
Strategies in Bioanalytical Method Development
The high specificity achievable by tandem mass spec trometry in MRM mode can be advantageously exploit ed in several ways when developing a bioanalytical method. Sample extraction can often be simplified to a single step procedure. This may be solid-phase extrac tion (SPE), liquid-liquid partition or protein precipita tion, depending on the nature of the analyte and/or the biological matrix involved. A comparison of these three extraction methods is given in Table IV . The strategy is to aim for maximum analyte recovery, thereby enhanc ing assay sensitivity, rather than for sample `cleanliness' as long as the extraction conditions do not lead to ad verse chromatography, to blocking of the LC interface or to interference with the ionisation process in the mass spectrometer. Simple extraction procedures are also favoured because they can be readily automated.
The extent of chromatographic separation required is usually minimal when a highly specific detector such as a mass spectrometer is used. Over 10 years ago, Covey and coworkers reported the use of short chromatograph ic columns (ca. 3 cm in length) in conjunction with MS/ MS detection for rapid drug bioanalysis20). Today, short LC columns of 3-5 cm in length are commonplace for rapid LC-MS/MS bioanalysis30-34). Using this approach, chromatographic analysis times of 2-3 minutes are typi cal, and analysis times as short as 30 seconds have been claimed. It is worth noting, however, that if the analyte is insufficiently separated from the solvent front, ion ad duct formation, ion suppression or interference from po lar coextractives may occur that can adversely affect the nerformance of the hioanalvtical method. The drug concentration analysed in chromatogram (a) was 100 times greater than that in chromatogram (b)29).
The low liquid flow rate of the electrospray interface permits the use of narrower bore LC columns (e.g. 1-2 mm i.d.) to `sharpen' the chromatographic peak and this, in turn, improves assay sensitivity. One main draw back of using narrower columns is that they are more prone to blockage. Analytical internal standards are usually used in quan titative analyses to improve the precision and accuracy of the method. As with any bioanalytical mass spectro metric method, the stable isotope-labelled analogue is the ideal internal standard as it exhibits virtually identi cal physicochemical properties to those of the analyte of interest, while the difference in mass enables the analyte to be separated from the internal standard. The stable isotopes that are commonly used include 13C 15N and 2H. analyte by using a low orifice or cone voltage. Excessive in-source fragmentation can reduce assay specificity. Ideal MS/MS conditions would involve the dissociation of the precursor ion to a single fragment ion of very high intensity that is structurally specific to the analyte. Op timisation of collision conditions to obtain mass spectral characteristics close to this ideal is accomplished by varying the collision energy and collision gas tension. Al teration of the mass resolution for the two mass analysers (in the case of tandem MS) also provides a means of compromising between sensitivity and specificity.
It is important to note that specificity towards the ana lyte is often inadequately assessed during method valida tion because the control biological matrix to which the analyte is added does not, by definition, contain any of the analyte's metabolites that may interfere. Such inter ference is not normally a major problem for bioanalytical mass spectrometric methods, because the metabolites usually have masses which are different to that of the parent drug. However, metabolites such as N-oxides, glucuronides and sulphates can potentially be converted back to the parent drug under conditions in the ion source of the mass spectrometer, and such metabolites could interfere unless first separated during LC.
Bioanalytical Method Validation
For the generation of reliable pharmacokinetic data, it is important that the bioanalytical method used is ade quately validated. Accordingly, the method needs to be validated with respect to linearity, accuracy, precision, recovery, sensitivity, specificity, analyte and internal standard stability (in extracts prior to injection into the liquid chromatograph) and the effect of sample dilution. The stability of the analyte in the biological matrix dur ing the period of deep-freeze storage prior to bioanalysis needs to be verified. The storage of quality control bio logical samples together with, and for the same period, as the test biological samples is good practice. Prior to the analysis of each batch of study samples, it is also necessary to establish that the LC-MS/MS equipment is operating within specification, the so-called system suitability test. Within each batch of study samples, sufficient calibration and quality control standards must be included. Results from each batch can only be accept ed if the results of the calibration and quality control standards fulfil preset criteria determined during method validation.
Details of the guiding principles of bioanalytical method validation have been published in a seminal paper by Shah et all') and further discussed by others3~`10). Furthermore, rigorous validation of quan titative LC MS computer software is becoming necessa ry for compliance with GLP requirements41>
Applications of Bioanalytical LC-MS/MS to Pharma cokinetic/Toxicokinetic Studies
While conventional HPLC with UV detection is still extensively used for bioanalysis, increasingly , the tech nique of choice is becoming LC-MS/MS. Several phar maceutical companies prefer LC-MS/MS for bioanaly sis of nonclinical and clinical samples. It may be true that the high sensitivity of LC MS/MS is not always re quired for toxicity studies where the dose levels ad ministered and subsequent systemic exposure may be quite high. However, the benefits of specificity, speed of analysis and versatility of LC-MS/MS often justify the much greater capital outlay for this instrumentation. A comparison between LC-MS/MS and HPLC UV for bioanalysis is summarised in Table V. There are numerous applications of bioanalytical LC MS/MS described in the scientific literature and conse quently this article is selective in citing only some recent examples so as to illustrate the bioanalytical capability and potential of LC-MS/MS systems equipped with API interfaces.
In general, most LC-MS/MS bioanalytical methods tend to employ simple procedures , often only a single step, for biological sample extraction (Table IV) . These include protein precipitation by organic solvents33, 42, 43) or by acids"). Solid-phase extraction (SPE) using com mercially prepacked cartridges is also very popular in bioanalytical LC-MS/MS32,34,45-47) because the proce dure can be readily automated. In some methods , column-switching is included so as to reduce the amount of endogenous coextractives that would otherwise be un avoidably loaded onto the analytical column33, 43, 44, 48) .
Single-step liquid-liquid partition is also employed for LC-MS/MS bioanalysis and in some cases enables a quantification limit of low pg/ml to be achieved31, 49 51) even where this approach has been considered to be too crude for HPLC-UV bioanalysis. Multi-step liquid-liq uid partition can often produce very `clean' extracts for bioanalysis as exemplified by the determination of reser pine in plasma where the use of liquid-liquid partition gave a four-fold improvement in quantification limit com pared to solid-phase extraction47).
API together with MS/MS detection not only pro vides high assay specificity but also one of the most sen sitive forms of detection available. It may not be meaningful to compare the sensitivity of various types of chromatographic detector towards a particular analyte as sensitivity is often compound-dependent . In general however, picograms per millilitre quantification limits are commonplace for API LC-MS/MS methods while nanogram per millilitre levels are typical for GC or HPLC methods based on non-mass spectrometric detec tors. Some recent examples include the determination of sumatriptan34), reserpine47), amlodipine49), fenticona zole52) and tamsulosin53) in biological fluids , which demonstrated that LC-MS/MS provided a notable im provement in sensitivity compared to the original methods.
As mentioned earlier, the simplicity of sample prepara tion for bioanalytical LC-MS/MS methods facilitates the use of automated solid-phase extraction procedures for high throughput bioanalysis. One popular recent de velopment is that of the 96-well micro preparation SPE system for high throughput sample preparation54-56) Analyte on the extraction cartridges is eluted into the "deep" wells of a 96-well microplate which can be placed directly onto the autoinjector of a LC-MS/MS machine. This approach, using microplate technology, solves the 'bottleneck' problem in LC-MS/MS bioanaly sis where the rate-limiting step is often sample prepara tion and not instrument analysis time. Some 400 biologi cal samples can be analysed in 24 hours using such auto mated extraction technology.
An alternative to automated solid-phase extraction is on-line sample extraction coupled directly to the LC sys tem. Van der Hoeven and coworkers reported on the use of a precolumn connected directly to a liquid chromato graph57). Samples were loaded onto the precolumn and following washing, its contents were backflushed onto the analytical column for subsequent MS/MS detection. With this approach, plasma and urine samples could be analysed directly without additional clean-up.
Since the electrospray interface is theoretically a con centration detector and its design is compatible with low er liquid flow rates, the use of narrower bore LC columns to give `sharper' chromatographic peaks can be employed increase sensitivity58). The low solvent flow rate of electrospray is also ideally suited for coupling a capillary electrophoretograph or a micro-column chro matograph to a mass spectrometer59-,61). A variant of the electrospray that is capable of coping with sub microlitre per minute flow rates, is often known as nanoelectrospray or nanospray. Although this interface has so far been used primarily for certain applications such as the analysis of peptides and proteins61-63) and the separation of chiral compounds64), the potential of CE-MS/MS for routine bioanalysis is still being realised. Recently, Wachs and coworkers described an improved self-aligning liquid junction electrospray inter face for CE-MS, which was used to separate a mixture of nine sympathomimetic drugs in urine65).
The effect of several different mobile phase buffer components on the ionisation efficiencies of a series of model compounds has been studied with the aim of im proving sensitivity66). These workers concluded that for bioanalysis using negative ion APCI, the use of formic acid as the pH modifier should be avoided because it sup presses ion formation from the analyte. The use of am monium acetate as the mobile-phase buffer for acidic analytes gave reasonably good results and the use of bas ic mobile phases containing volatile amines was tenta tively recommended for improving sensitivity.
For the separation of drug enantiomers, LC-MS (or LC-MS/MS) with the API interface and narrow LC columns (ca. 2 mm i.d.) for reversed phase67,68) and nor mal phase chromatography69) has been reported.
The virtues of LC MS/MS for bioanalysis are further extolled with the use of ion-trap technology. The cost of ion-trap mass spectrometers is about half that of triple quadrupole machines. Henion and coworkers described the design of an API interface for ion-trap mass spec trometers with novel differential pumping70,71). The ap plication of this technology to pharmaceutical bioanaly sis has been described using steroids as model compounds32). However, because of instrument design, bioanalytical methods involving ion-trap mass spectrom eters are not expected to be as sensitive as those involv ing triple quadrupole machines.
In sensitivity terms, LC MS/MS compares favoura bly with immunoassay.
However, immunoassay methods often suffer from lack of specificity owing to cross-reactivity problems caused by structurally related compounds or metabolites, or even endogenous sub stances. It is for this reason that LC-MS/MS is often used to assess the specificity of immunoassay methods prior to their use in pharmacokinetic studies72.73).
In this current era of combinatorial chemistry, there is a huge demand for a bioanalytical technique that is both specific and versatile for the detection of a range of relat ed compounds. The applications of mass spectrometry including LC-electrospray-MS and tandem MS to com binatorial chemistry have been reviewed74). The applica tion of LC-MS/MS to the bioanalysis of samples from animals dosed with several drug candidates simultane ously (so-called cassette-dosing) has also been demon strated75) and is ever increasing.
As far as pharmacokinetic/toxicokinetic studies are concerned, the greater sensitivity and specificity of LC MS/MS enables pharmacokinetic data to be obtained that are usually more comprehensive than would be achievable using other bioanalyticaltechniques.
In toxicokinetic studies, for example, a drawback of HPLC-UV is that its poorer sensitivity may lead to more animals being used in order to obtain sufficient plasma for an adequate description of the test compound's phar macokinetics. Often in toxicity studies, particularly those by the dietary route, HPLC-UV is insufficiently sensitive to measure plasma drug concentrations beyond the first few hours after dosing, or after the low dose lev el. Ideally drug concentrations at every time point sam pled up to and including the last time point in a dosage in terval, should be measurable so as to adequately describe the drug's pharmacokinetics. Furthermore, the inferior specificity of HPLC-UV can lead to chromato graphic interference from one or more metabolites dur ing the repeated dose regime of toxicity studies, owing to accumulation resulting in relatively greater concentra tions of these metabolites. What was an acceptable HPLC UV method for single dose toxicity or phar macokinetic studies may become inappropriate for repeated dose toxicity studies.
Because relatively longer times are required for ade quate chromatographic separation when using HPLC UV, the latter technique is slower than is LC-MS/MS, typically ten times slower. Often in first administration tolerance/pharmacokinet ic studies in humans (Phase I), it is not always possible, using HPLC-UV, to measure plasma drug concentra tions at the relatively lower doses that are initially ad ministered owing to safety considerations. Thus phar macokinetic data cannot be obtained that would have been useful in guiding dose escalation during the Phase I study. The use of LC-MS/MS should generally make it possible to measure drug concentrations and to deter mine pharmacokinetic parameters for even the initial "starting" dose in Phase I studies .
The drawbacks of HPLC-UV with respect to sensitivi ty, specificity and rate of sample analysis are shared, but generally to a lesser extent, by other common bioanalyti cal techniques that may be used to generate pharmacoki netic data. Such other techniques include HPLC with fluorescence or electrochemical detectors, and gas chro matography with nitrogen-phosphorus, electron capture or mass spectrometric detectors.
Future Trends
Although the use of API LC-MS/MS for bioanalysis began only some ten years ago, growth in the develop ment and applications of this technology has been phenomenal. The performance to cost ratio of the neces sary equipment is being improved continuously. The ad vent of the ion-trap as a tandem MS quantitative detec tor for routine bioanalysis probably represents a notable breakthrough in terms of performance-cost ratio despite some compromise in performance, such as sensitivity and precision, when compared with triple-quadrupole instruments. Gone are the days when there were only one or two machines in a typical mass spectrometry laboratory when equipment designs had to cope with a wide range of applications needing multi-inlets and mul ti-ionisation capability, etc. Today, instrument manufac turers are more focused in their product range and the equipment is increasingly dedicated to specific applica tions. Also, with the advances in pumping technology, electronics and software control, instrument manufac turers are able to design machines that are smaller, sim pler to use and with a much better performance to cost ratio. A new generation of LC-MS interfaces that are more amenable to the use of non-volatile buffers and ion pairing reagents are being developed.
The technology for automated sample preparation con tinues to improve. As the range of available packing materials for solid-phase extraction increases, more and more bioanalytical methods will be based on this extrac tion approach. In the near future, automated SPE sys tems or on-line precolumn switching capabilities will no doubt become an integral part of a bioanalytical LC MS/MS system. Other automated SPE methodology will be based on immunoaffinity columns and other molecular recognition approaches.
The use of CE-MS/MS will also widen the boundaries for routine bioanalysis in terms of resolution capability for chiral compounds and compounds that have similar masses and physicochemical properties. The coupling of CE to MS/MS will improve the sensitivity and through put of the potentially powerful technique of CE. Although CE is already employed for a number of bioanalytical applications, its use as a routine bioanalyti cal technique still requires further development.
Conclusions
As a result of the development of API interfaces, LC MS/MS is often the preferred technique for routine bioanalysis during drug discovery and development. There is no doubt that this technology will continue to play an increasingly important role in bioanalysis. As a chromatographic detector, it is both universal and specific. Universal because the modern LC-MS inter faces are compatible with a large variety of compound classes or molecular weights, and specific because the mass spectrometer can be "tuned" to detect only the analyte (s) of interest. Bioanalytical methods based on LC-MS/MS almost always provide better specificity, sensitivity and sample throughput than LC methods with other detection systems. The high sensitivity achievable with MS or MS/MS detection facilitates pharmacokinetics/toxicokinetics studies of more potent drugs in small laboratory animal species such as mice and marmosets and at relatively low dose levels.
Development of the technology will continue towards more automation and to include an even wider range of applications. The cost of equipment, although still rela tively high, has decreased. LC-MS/MS is becoming more user friendly and robust, and this technology will soon no longer be considered usable solely by the specialist.
